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Rheumatoid arthritis
AbstrAct
Objective Patients with rheumatoid arthritis (ra) have 
an increased risk of serious infections. comparing 
infection rates across ra populations is complicated 
by differences in background infection risk, population 
composition and study methodology. We measured 
infection rates from five ra registries globally, with the 
aim to contextualise infection rates from an ra clinical 
trials population.
Methods We used data from consortium of 
rheumatology research of north america (cOrrOna) 
(USa), Swedish rheumatology Quality of care register 
(Sweden), norfolk arthritis register (UK), cOrrOna 
international (multiple countries) and institute of 
rheumatology rheumatoid arthritis (Japan) and an ra 
clinical trial programme (fostamatinib). Within each 
registry, we analysed a main cohort of all patients with 
ra from January 2000 to last available data. infection 
definitions were harmonised across registries. Sensitivity 
analyses to address potential confounding explored 
subcohorts defined by disease activity, treatment change 
and/or prior comorbidities and restriction by calendar 
time or follow-up. rates of infections were estimated 
and standardised to the trial population for age/sex and, 
in one sensitivity analysis also, for Health assessment 
Questionnaire (HaQ) score.
Results Overall, age/sex-standardised rates of 
hospitalised infection were quite consistent across 
registries (range 1.14–1.62 per 100 patient-years). 
Higher and more consistent rates across registries and 
with the trial programme overall were seen when adding 
standardisation for HaQ score (registry range 1.86–2.18, 
trials rate 2.92) or restricting to a treatment initiation 
subcohort followed for 18 months (registry range 0.99–
2.84, trials rate 2.74).
Conclusion this prospective, coordinated analysis of ra 
registries provided incidence rate estimates for infection 
events to contextualise infection rates from an ra clinical 
trial programme and demonstrated relative comparability 
of hospitalised infection rates across registries.
InTROduCTIOn
Patients with rheumatoid arthritis (RA) have 
an increased risk of infection due to both 
direct disease-related effects and immuno-
suppressive treatment-related effects of RA 
therapies (eg, corticosteroids and tumour 
necrosis factor antagonists).1–7 For ethical 
reasons, modern RA drug trials are generally 
Key messages
What is already known about this subject?
 ► Patients with rheumatoid arthritis (ra) have an 
increased risk of serious infections, and the 
incidence of infections is affected by many factors.
What does this study add?
 ► We have compared the infection rate in five large 
registries of ra and one clinical trial programme 
by harmonising the definition of infection, and we 
found that, overall, age/sex-standardised rates of 
hospitalised infection were quite consistent across 
registries, and with the incidence rate of patients 
in the fostamatinib clinical trial programme, which 
was the motivating factor behind this study. 
 ► this was especially so when standardising rates 
additionally for Health assessment Questionnaire 
score, a measure of frailty.
How might this impact on clinical practice?
 ► With appropriate standardisation, hospitalised 
infection rates were reasonably comparable across 
the ra registries. 
 ► good understanding of underlying infection rates, 
and determinants for their variation, is important 
clinically when evaluating potential infection 
adverse effects of ra treatments, both in clinical 
practice and in drug development and approval.
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limited to 6 months of placebo-controlled follow-up, 
and patients without response in any study arm can be 
rescued to active treatment. Consequently, placebo-arm 
data are quite limited in both patient numbers and 
follow-up duration, adding uncertainty around the safety 
profile of new products for rare and long-term outcomes. 
Observational data may be used to provide background 
rates as context for safety events observed in clinical trial 
programmes.8 9 Typically, published data have been used 
for such purposes, but reliance on published data has 
challenging limitations, including differences in patient 
populations, geographical differences, variability in 
outcome definitions, lack of concurrent data and anal-
yses that are inadequate for the specific question at hand 
(eg, typically only a crude overall rate rather than age/
sex stratum-specific rates).
We sought to improve on existing methodology for 
contextualising trial data from the active treatment 
group with observational data, in order to support safety 
assessment for an RA drug development programme, 
given the limited placebo data from the trial programme. 
By context, it is understood ‘to place (a word, event, etc.) 
into a particular or appropriate context for the purpose of inter-
pretation or analysis’, that is, here specifically to provide 
such external context for infection rates observed in 
the trials. The specific drug, fostamatinib, an oral Syk 
inhibitor, was being developed for the treatment of RA 
but was discontinued in this indication following inad-
equate phase III efficacy results.10–12 While the phase 
III programme was ongoing, we established a prospec-
tive, coordinated approach across multiple RA regis-
tries to compile, analyse and interpret real-world safety 
data in patients with RA to contextualise the clinical 
trial programme.13–16 Here, we describe and compare 
real-world rates of infection in patients with RA from 
diverse regions globally and discuss how these provide 
context to rates of infection observed in a clinical trial 
programme.
MeTHOds
The methods of the overall safety contextualisation 
programme have been described elsewhere.13 In brief, 
we: (A) included several existing registries with individ-
ual-level patient data on infection and established a new 
registry to enhance geographic coverage across Eastern 
Europe, Latin America and Asia; (B) harmonised infec-
tion outcome definitions across registries; (C) identified 
baseline differences in demographics, disease history 
and disease activity between registry cohorts and the 
clinical trial programme; (D) identified key predictors 
for infection incidence in the registries; (E) calculated 
infection incidence rates stratified by these predictors; 
(F) computed aggregate-level incidences standardised 
to the clinical trial programme; and (G) assessed their 
robustness across sensitivity analyses including different 
definitions of registry cohorts and follow-up times.
RA registries
Five RA registries—Consortium of Rheumatology 
Research of North America (CORRONA; USA),17–19 
Swedish Rheumatology Quality of Care Register (SRR; 
Sweden),20–22 Norfolk Arthritis Register (NOAR; 
UK),23–25 CORRONA International (a new multina-
tional registry)13 26 and Institute of Rheumatology Rheu-
matoid Arthritis Cohort (IORRA; Japan)6 7 27–29—were 
selected. Selection was based on several considerations, 
partly focused on optimising comparability with patient 
populations in a typical RA clinical trial programme: (1) 
well-established, scientifically rigorous registries with 
appropriate design and quality for this study; (2) global 
representation to better geographically match the clin-
ical trial programme; (3) size and data quality, including 
availability of longitudinal RA-specific data (eg, disease 
activity measures and treatments); and (4) longitudinal 
Table 1 Details of the five included real-world RA registries
Consortium of Rheumatology Researchers 
of North America (CORRONA)
The CORRONA registry, established in 2001, is a US-based longitudinal registry 
of patients with RA (n=25 000) and psoriatic arthritis (n=4000).
Swedish Rheumatology Quality of Care 
Register (SRR)
The SRR was initiated in the mid-1990s and currently 
encompasses >40 000 patients with RA.
Norfolk Arthritis Register (NOAR) The NOAR in the UK, established in 1989, is an early arthritis inception cohort 
registry that currently comprises over 4000 patients, identified from primary and 
secondary care.
Institute of Rheumatology Rheumatoid 
Arthritis (IORRA)
The IORRA cohort was established in 2000 at the Tokyo Women’s Medical 
University, Japan. Approximately 5000–5800 patients participate; more than 
11 000 patients have been enrolled at least once.
CORRONA International Based on the methodology employed in the CORRONA US registry, this new 
registry was established in 2011 as a joint collaboration with AstraZeneca. By 
the end of 2012, a total of 5790 patients had been included from 10 participating 
countries.
RA, rheumatoid arthritis.
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capture of comorbidity events with sufficient data detail 
and validity.
Features of each registry are described in detail in 
table 1. CORRONA, established in 2001, is a US-based 
longitudinal registry of >25 000 patients with RA.17–19 
SRR was initiated in the mid-1990s and currently encom-
passes >40 000 patients with RA.20–22 NOAR, established 
in 1989, is an early arthritis inception cohort registry 
that currently comprises >4000 patients, identified 
from primary and secondary care.23–25 The CORRONA 
International registry, based on CORRONA US meth-
odology, was set up in 2011 primarily for this study as 
a stand-alone multinational registry in a collaboration 
with the study sponsor to enhance geographic represen-
tativeness of the registries included in this programme. 
Information about outcomes in general, and adverse 
events specifically, were selected and defined influ-
enced by the goals of the overall project ensuring that 
CORRONA International data collection paralleled the 
definitions commonly used in clinical trials. The mech-
anism of ensuring data quality and validity followed the 
established model of CORRONA US, using automated 
electronic algorithms to identify missing, erroneous or 
conflicting entry of data in addition to a thorough data 
quality control performed by a dedicated CORRONA 
team.19 By the end of 2012, 5790 patients had been 
included into this registry from 10 countries in Latin 
America (Brazil, Mexico and Argentina), Central/
Eastern Europe (Czech Republic, Hungary, Poland, 
Romania, Russia and Ukraine) and Asia (India).13 26 
The IORRA cohort was established in 2000 in Japan. 
Annually, 5000–5800 patients participate, and the total 
number of patients who have been examined at least 
once exceeds 11 000.6 7 27–29
The clinical trial programme
The clinical trial data included data from all fostamati-
nib-exposed patients in the phase II-III RA programme 
including open-label extension studies, with data cut-off 
of 19 March 2013 (n=3240).10–12 Key relevant exclusion 
criteria of the overall programme for the current study 
were recent steroid use, active or recent significant infec-
tions and neutropaenia.
definition of study cohorts and subcohorts
Within each registry, we defined a main cohort of all 
adult patients (age 18 years or older) diagnosed with RA 
according to each registry’s definition, from 1 January 
2000 or the earliest time point thereafter. No additional 
inclusion/exclusion criteria were used.
To evaluate the influence of alternative cohort selec-
tion criteria on infection incidence and comparability 
with the clinical trial population, we created subcohorts 
for sensitivity analysis, defined by criteria related to: 
disease activity, treatment status/change and/or prior 
comorbidities (figure 1).
data collection and baseline characteristics
For each analysis, baseline was defined consistently across 
registries as the point when registry patients fulfilled the 
cohort membership conditions in each main or sensitivity 
analysis. Baseline characteristics in each registry were 
then defined based on available data (online supplemen-
tary table 1). In all cohorts, start and stop dates of RA 
therapies were recorded at each follow-up visit, and most 
other characteristics were updated regularly depending 
on data collection and visit schedules, often at each visit, 
and were used both to define baseline characteristics in 
each main cohort or subcohort at the respective index 
date and to define subcohorts as described above. Base-
line demographic and disease activity measures were cate-
gorised in predefined categories and included age (<50, 
50–65 and ≥65 years), gender, 28-joint disease activity 
score (DAS28; <3.2, 3.2–5.1 and ≥5.1), C reactive protein 
(CRP) (<6, 6–10, 10–16 and ≥16 mg/L), erythrocyte sedi-
mentation rate (ESR) (<28, 28–42 and ≥42 mm/h), rheu-
matoid factor (RF) positivity (RF + yes/no) and nation-
ally validated Health Assessment Questionnaire (HAQ) 
score (<1.1, 1.1–1.8 and ≥1.8).
Outcome definitions and follow-up
The primary infection outcome was hospitalised infec-
tion. In addition, tuberculosis and herpes zoster were 
also included as specific infection outcomes. Outcome 
definitions were agreed with each registry to optimise 
validity and comparability across registries and the clin-
ical trial dataset, depending on the type and level of 
data available in each registry (online supplementary 
table 2). Briefly, the definition of hospitalised infection 
was based on reported infection-related serious adverse 
events hospitalised for this cause in the clinical trials, 
linked inpatient registry infection discharge codes in 
SRR and NOAR, patient-reported infection hospitalisa-
tion in IORRA and physician-reported infection hospital-
isations in CORRONA and CORRONA International. In 
each analysis, only the first event of the relevant outcome 
during follow-up was included, both for trial and registry 
data.
For the primary analysis, follow-up began at the later 
date of entry for a patient into the registry or 1 January 
2000. In the subcohorts, follow-up began at the later date 
of entry into the subcohort (based on subcohort eligi-
bility criteria) or 1 January 2000. In all analyses, follow-up 
ended at the earliest of the following: outcome, death, 
last date of follow-up in the registry, loss to follow-up or 
31 July 2013.
Predictors of infection events in each registry
For each outcome and registry, we assessed the association 
between predefined covariates and the outcome using 
Cox regression. The covariates included age, sex, HAQ 
score, BMI, RA treatment history, indices of baseline RA 
disease activity and several typical trial exclusion criteria 
related to comorbidity,10–12 including recent steroid treat-
ment, relevant in this study. These analyses determined 
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which covariates would be used for standardisation of 
incidences from the RA registries. Apart from age and 
sex, HAQ score was the strongest predictor of infection 
events across registries. Consequently, age (four catego-
ries) and sex were used as basic standardisation factors 
(ie, eight strata), and HAQ score (three categories) was 
added for standardisation in one sensitivity analysis (ie, a 
total of 24 strata).
sensitivity analyses
Sensitivity analyses were conducted by changing the 
variables of the main analysis , and were used to assess 
the robustness of estimated rates from each registry to 
confounding by various factors (online supplementary 
table 3). The sensitivity analyses applied subcohort defi-
nitions including selected study inclusion and exclusion 
criteria to reflect typical trial criteria (figure 1), restricted 
follow-up time (in calendar time or by truncation at 18 
months) and introduced additional standardisation for 
HAQ score. Sensitivity analyses were only applied to the 
main outcome (hospitalised infections).
data management and statistical analysis
Each registry provided counts and percentages of descrip-
tive characteristics at baseline. For the follow-up, they 
provided number of cases and associated person-time for 
each study outcome, within strata defined by age, sex and 
HAQ score. A central analysis used the stratum-specific 
data to calculate incidence rates for each registry, stand-
ardised to the distribution of the RA trial programme 
patient population for the selected standardisation vari-
ables, with CIs based on a gamma distribution.30 31 The 
clinical trial rate was calculated with exact Poisson 95% 
CIs. The estimated incidence rates were based on indi-
vidual records with non-missing observations on all vari-
ables involved (outcome, age, sex, and—where used—
HAQ score). No patients had missing age or sex, whereas 
5.4% of patients had missing HAQ scores.
Individual data were maintained by each registry 
throughout the study, and all analyses of patient-level data 
were done locally within the registry for each RA cohort, 
without pooling of individual data across registries. Study 
Figure 1 Definitions and relationship between the main cohort (here denoted cohort A) and nested subcohorts within the 
registries that are used for the main and some subcohort analyses. Note that cohorts B and C1 are intermediate steps and 
were not included in the final subcohort sensitivity analyses. Note also that the C1 and C2, as well as the C1a and C1b, 
subcohorts are partly overlapping, as some individuals may be included in one subcohort at one point in time and then at 
another (later) point in the other (given the longitudinal character of the data). 1Main registry cohort of patients in registry 
from 1 January 2000 (or earliest first date after 1 January 2000) and baseline at 1 January 2000 or cohort entry. 2Subcohort 
defined by selection of patients with active RA (patients with seropositive/erosive RA and with >4+4 tender/swollen joints from 
28-joint counts). 3Subcohort defined by selection of patients with treatment switch/addition who are previously biologicals 
naïve (inadequate response to MTX/DMARDs). 4Subcohort defined by selection of patients with treatment switch/addition 
who have been treated previously with biologicals (inadequate response to biologicals). *At time of treatment change/initiation 
(‘switch’), excludes patients with history of cancer; major CV event in the previous 6 months (myocardial infarction, unstable 
angina, stroke, pulmonary embolism or heart failure); oral steroids prednisolone (or equivalent) >10 mg/day—as markers of 
potential risk for cancer, CV disease and infections—in alignment with the corresponding relevant trial exclusion criteria. CV, 
cardiovascular; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid arthritis.
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members and registry staff remained blinded to trial data 
that were not already in the public domain. All registries 
had appropriate ethical approvals and patient consents.
ResulTs
Baseline characteristics
Table 2 summarises the numbers of patients and the 
baseline characteristics for each registry’s main cohort 
and the trial population. Demographic characteristics 
at baseline of the main registry cohorts showed typical 
features of patients with RA in a real-world setting, as 
females account for 70%–85% of the population and 
35.4%–54.1% of the patients were 60 years of age or older 
at baseline; in contrast, the trial population was younger 
due to the range of trial inclusion and exclusion criteria 
applied but with a similar sex distribution. There were 
larger differences in baseline disease activity and clin-
ical characteristics. Patients from the trial programme 
had higher DAS28, HAQ scores, swollen joint counts 
(data not shown) and ESR values than registry patients, 
whereas differences in CRP were less pronounced 
(table 2). There were also differences between the trial 
population and the registry cohorts and across these 
cohorts, with regards to baseline comorbidities (with 
the definitions available for each data source) (table 2). 
Treatment from baseline varied considerably across 
registries and the trial population, reflecting the varying 
selection criteria, as well as background differences in 
the various populations. In the different sensitivity anal-
yses, some of these baseline differences were reduced; 
for example, in sensitivity analyses 2 and 7, the biologi-
cals-naïve patients switching or adding treatment (inad-
equate responders to methotrexate/disease-modifying 
antirheumatic drug (MTX/DMARD-IR)), MTX treat-
ment was more similar across registries, although many 
differences remained (online supplementary table 4).
Incidence of hospitalised infections, tuberculosis and herpes 
zoster
In the main analysis, crude rates of hospitalised infections 
differed quite notably across the five registry cohorts 
(range 1.16–2.48 per 100 person-years (PY)), whereas 
after age-standardised and sex-standardised incidence 
rates were fairly consistent across the registry cohorts 
(range 1.14–1.62 per 100 PY). The rate was higher in the 
RA trial programme cohort (2.92 per 100 PY) (tables 3 
and 4, figure 2A).
For a number of the sensitivity analyses, the stan-
dardised incidence rates of hospitalised infection showed 
a higher consistency across the registry subcohorts and 
with the trial data. This was particularly evident for the 
analysis standardised for HAQ score in addition to sex 
and age (sensitivity analysis 9), where the registry rates 
were higher than in each of the main registry cohorts 
(range 1.86–2.18 per 100 PY across registry subcohorts), 
and more consistent with the incidence rate 2.92 per 100 
PY in the full RA trial cohort (table 4, figure 2B). A similar 
tendency to greater similarity across datasets (except 
IORRA) was seen for sensitivity analysis 7 in biologi-
cals-naïve patients switching or adding treatment (MTX/
DMARD-IR), focusing on the first 18 months after treat-
ment initiation (table 4, figure 2C; range 2.10–2.84 per 
100 PY across registry subcohorts except IORRA), where 
the rate in the RA trial programme MTX-IR cohort was 
2.74 per 100 PY.
Incidence of tuberculosis and herpes zoster was low in 
all cohorts, and in some cases so rare that stable rates 
could not be estimated. Standardised incidence rates for 
tuberculosis in the main cohorts were lower in CORRONA 
and SRR compared with IORRA and CORRONA Inter-
national, largely reflecting known regional differences 
(table 3). Similarly, standardised incidence rates for 
hospitalised herpes zoster and all herpes zoster were 
lower in CORRONA and CORRONA International 
compared with IORRA (table 3). In the trial programme, 
exclusion criteria for latent tuberculosis infection should 
reduce the incidence; although events were few, rates 
appeared to be within the range of the registries for these 
outcomes.
dIsCussIOn
In this study, we have successfully implemented a novel 
approach to using observational data for contextualising 
infection rates observed in a clinical trial. Through a 
prospective, coordinated analysis of several RA registries, 
we have demonstrated the ability to provide improved 
consistency of data across registries, resulting in more 
extensive and comparable information for contextual-
ising trial rates.
It is interesting to note that incidence rates of hospital-
ised infections, which as crude measures differed quite 
notably across five registry cohorts (range 1.16–2.48 per 
100 PY, ie, a ratio of 2.1), were considerably more consis-
tent when standardised for age and sex (range 1.14–1.62 
per 100 PY, ratio 1.4). This indicates that age/gender 
standardisation to reduce confounding is critical for 
comparing infection rates across registries and when using 
them to contextualise a global clinical trial programme. 
Further standardisation for HAQ score (beyond just age 
and sex) also appeared to be of importance to provide 
more comparable data from the registries, providing 
higher standardised rates for most registries (reflective 
of the higher HAQ scores among trial participants) and 
closer to the trial programme rates. This result is consis-
tent with the importance of general disability in the 
susceptibility of patients to infections.32 33 Despite differ-
ences across registries in, for example, comorbidity and 
oral corticosteroid treatment, we did not find that these 
factors were important predictors across registries of 
infection incidence rates when age, sex and HAQ were 
already considered. This may relate to differences in the 
way these are captured in the various registries (which 
could exaggerate differences) or it may indicate that age, 
sex and HAQ differences, which better capture infection 
group.bmj.com on March 15, 2018 - Published by http://rmdopen.bmj.com/Downloaded from 
6 Yamanaka H, et al. RMD Open 2017;3:e000498. doi:10.1136/rmdopen-2017-000498
RMD Open
Table 2 Baseline characteristics of patients with RA in the main cohorts from five RA registries and one RA clinical trial 
programme
Variable
Fostamatinib 
trials CORRONA SRR NOAR
CORRONA 
International IORRA
(n=3240) (n=24 176) (n=18 527) (n=1564) (n=3867) (n=10 255)
Demographic and RA disease characteristics, N (%)*
  Sex Male 551 (17.0) 5791 (24.0) 5499 (29.7) 470 (30.1) 584 (15.1) 1829 (17.8)
Female 2689 (83.0) 18 385 (76.0) 13 028 (70.3) 1094 (69.9) 3283 (84.9) 8426 (82.2)
  Age, years <50 1174 (36.2) 5973 (24.7) 4268 (23.0) 390 (24.9) 1260 (32.6) 3016 (29.4)
50–<60 1123 (34.7) 6777 (28.0) 4235 (22.9) 377 (24.1) 1237 (32.0) 3033 (29.6)
60–<70 712 (22.0) 6302 (26.1) 5084 (27.4) 376 (24.0) 933 (24.1) 2727 (26.6)
≥70 231 (7.1) 5124 (21.2) 4940 (26.7) 421 (26.9) 437 (11.3) 1479 (14.4)
  Race† White 2296 (80.5) 21 654 (90.0) NA 1542 (99.2) 2455 (66.2) 0 (0.0)
Asian 73 (2.6) 372 (1.5) NA 4 (0.3) 423 (11.4) 10 255 (100.0)
Black 123 (4.3) 1673 (7.0) NA 2 (0.1) 34 (0.9) 0 (0.0)
Other 361 (12.7) 366 (1.5) NA 6 (0.4) 799 (21.5) 0 (0.0)
  Disease duration, years <5 1200 (49.2) 10 379 (43.2) 12 962 (70.4) 862 (55.1) 1518 (39.4) 4977 (48.5)
5–<10 549 (22.5) 4921 (20.5) 1619 (8.8) 474 (30.3) 1021 (26.5) 2078 (20.3)
≥10 688 (28.2) 8742 (36.4) 3819 (20.8) 228 (14.6) 1317 (34.2) 3200 (31.2)
  DAS28 <3.2 2 (0.1) 4345 (41.7) 3902 (24.1) 168 (25.0) 974 (31.5) 2692 (29.5)
3.2–<5.1 814 (25.2) 4097 (39.3) 6353 (39.2) 339 (50.4) 1260 (40.8) 4825 (52.9)
≥5.1 2410 (74.7) 1971 (18.9) 5964 (36.8) 166 (24.7) 857 (27.7) 1599 (17.5)
  HAQ score <1.1 708 (21.9) 15 018 (65.0) 10 167 (60.8) 699 (45.5) 1791 (50.1) 7131 (69.7)
1.1–<1.8 1354 (41.9) 6116 (26.5) 4629 (27.7) 443 (28.9) 1101 (30.8) 2095 (20.5)
≥1.8 1171 (36.2) 1983 (8.6) 1916 (11.5) 393 (25.6) 680 (19.0) 1008 (9.8)
  RF+ Yes 2022 (78.0) 9274 (72.4) 12 904 (71.7) 1103 (83.8) 2679 (76.6) 7683 (78.8)
  CRP (mg/L) <6 1182 (36.5) 3368 (56.9) 5106 (29.7) 155 (21.2) 976 (50.3) 4895 (49.8)
6–<10 549 (16.9) 917 (15.5) 3035 (17.6) 121 (16.6) 264 (13.6) 1277 (13.0)
10–<16 483 (14.9) 641 (10.8) 2782 (16.2) 145 (19.8) 216 (11.1) 1080 (11.0)
≥16 1026 (31.7) 994 (16.8) 6291 (36.5) 310 (42.4) 484 (24.9) 2574 (26.2)
  ESR (mm/h) <28 355 (11.3) 7341 (66.8) 10 511 (60.0) NA 1796 (58.1) 4350 (44.4)
28–<42 1394 (44.6) 1801 (16.4) 2995 (17.1) NA 586 (19.0) 1918 (19.6)
≥42 1380 (44.1) 1847 (16.8) 4001 (22.9) NA 710 (23.0) 3530 (36.0)
Comorbidities (medical history), N (%)*
  Diabetes 260 (10.7) 1883 (7.8) 834 (4.5) 129 (8.2) 402 (10.4) 246 (2.4)
  Coronary artery disease 23 (0.9) 1550 (6.4) 1460 (7.9) 40 (2.6) 268 (6.9) 152 (1.5)
  Hypertension 977 (40.1) 7455 (30.9) 1866 (10.1) 408 (26.1) 1555 (40.2) 772 (7.5)
  Peptic/bleeding ulcer 1678 (6.9) 456 (2.5) 104 (6.6) 209 (5.4) 242 (2.4)
  Liver disease 1141 (4.7) 124 (0.7) 19 (1.2) 93 (2.4) 121 (1.2)
Assigned treatment (treatments used from baseline), N (%)*
  Methotrexate 2757 (85.1) 15 609 (64.6) 13 240 (71.5) 528 (33.8) 2684 (69.4) 7664 (74.7)
  Other non-biological DMARD 374 (11.5) 7266 (30.1) 4151 (22.4) 379 (24.2) 1893 (49.0) 7818 (76.2)
  Biologicals 4 (0.1) 9217 (38.1) 132 (0.7) 15 (1.0) 491 (12.7) 1315 (12.8)
  Corticosteroids 1735 (53.5) 7214 (29.8) 7933 (42.8) 272 (17.4) 1165 (30.1) 6259 (61.0)
  NSAID/COX-2 2254 (69.6) 11 709 (48.4) 7764 (41.9) 2426 (62.7) 8947 (87.2)
*Percentages were calculated based on non-missing data.
†Each patient is listed in only one category; patients who reported mixed race are coded in the first relevant category of the four listed.
CORRONA, Consortium of Rheumatology Researchers of North America; COX-2, cyclooxygenase-2 inhibitors; CRP, C reactive protein; DAS28, 
disease activity score in 28 joints (DAS28 in the NOAR registry is calculated from CRP); DMARDs, disease-modifying antirheumatic drugs; ESR, 
erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IORRA, Institute of Rheumatology Rheumatoid Arthritis; NA, not available; 
NOAR, Norfolk Arthritis Register; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; RF+, rheumatoid factor positive; SRR, 
Swedish Rheumatology Quality of Care Register.
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risk across registries, may be partially correlated with 
these factors but more consistently measured.
When compared with the RA clinical trial popula-
tion, registry rates of hospitalised infection were in 
general lower; however, when sensitivity analyses were 
conducted, including of subcohorts of patients more 
similar to those in the trial population, the rates became 
more similar, suggesting an important influence and 
potential confounding of these variables, which could 
be removed by restriction. This implies that despite the 
fact that many baseline differences appeared to remain 
also in the sensitivity analyses (eg, online supplementary 
table 4), any remaining variability in baseline differences 
across cohorts has limited influence on rates of infec-
tion in these analyses. Additionally, for most registries, 
the rate of infection was higher in the first 18 months 
following a treatment change, a follow-up duration that 
is more similar to the trial programme. This finding is 
consistent with other published results and may reflect 
an increase in the risk of hospitalised infection related 
to the period following switch/addition of treatments 
in patients with active RA, which could be due to true 
increased risk to susceptible patients during that period 
and/or more active medical surveillance or management 
during that time and/or treatment discontinuation by 
susceptible individuals over time after a treatment switch, 
as suggested by previous literature.2 5 33 34 Another poten-
tial confounder is the availability of reimbursement cover 
for hospitalisation in a trial setting, which may contribute 
to higher rates of hospitalisation for trial participants in 
some countries.
These data therefore suggest that the main analysis 
in the registries, for example, using all data from 2000 
through end of study period, may provide a good esti-
mate of risk in the longer term but may underestimate the 
short-term risk in the period after a change in treatment 
(eg, add-on or switch). The sensitivity analysis truncating 
follow-up after 18 months likely provides a better estimate 
of the short-term risk of infection in selected populations 
and may provide a more appropriate context for clinical 
trial data regarding infection outcomes, given the rela-
tively short follow-up in most clinical trial programmes. 
The use of consistent baseline confounders, selection of 
patients meeting trial eligibility and length of follow-up 
are the key factors to providing contextual rates of hospi-
talised infection. The adjustments/standardisations are 
not specific to registry-specific confounders or treatment 
patterns and illustrate that variability remaining is rela-
tively limited and thus provides interpretation that is not 
registry specific.
The prospective approach to generating contextual 
observational data has several strengths that improve 
on reliance on available published data. In this study, 
these included: (1) working directly with registries to 
allow direct access to data sources, enabling appropri-
ately tailored analyses including standardisation and 
stratification for relevant variables and providing better 
support for sensitivity analyses and data interpretation; 
(2) a main analysis using a relatively unselected cohort 
over long follow-up from each registry (to maximise 
precision of event rate estimates), supplemented with a 
series of sensitivity analyses (to assess potential bias and 
variability in main analysis); (3) the selection of registry 
subcohorts in some sensitivity analyses to more closely 
resemble clinical trial populations in order to under-
stand how important these aspects are; (4) temporal 
matching to the current clinical trial programme to 
address potential changes in risk panorama, treatment 
patterns and disease risk over time; and (5) appropriate 
selection and improved comparability of outcome defi-
nitions across registries and with trial data, achieved by 
tailored registry definitions to better match the defini-
tions obtainable from the clinical trials, as well as from 
other registries.
Table 3 Numbers of events (person-time) and incidence rates of infections per 100 PY standardised by age and sex* (with 
95% CIs)†, in the main cohorts from five RA registries and one RA clinical trial programme
Outcome
Hospitalised 
infection Tuberculosis
Hospitalised
Herpes zoster
All
Herpes zoster
Incidence rate 
of hospitalised 
infection per 100 
PY (95% CI)*†
Fostamatinib trials 2.92* (2.44 to 3.46)† NC NC 1.14 (0.85 to 1.49)
CORRONA 1.30 (1.18 to 1.42) 0.04 (0.03 to 0.06) 0.02 (0.01 to 0.04) 0.66 (0.59 to 0.73)
SRR 1.62 (1.52 to 1.72) 0.02 (0.01 to 0.03) 0.01 (0.01 to 0.02) NA
NOAR 1.56 (1.30 to 1.88) NC NC NA
CORRONA 
International
1.50 (1.09 to 2.05) 0.35 (0.17 to 0.67) NC 0.26 (0.11 to 0.54)
IORRA 1.14 (1.05 to 1.25) 0.17 (0.13 to 0.22) 0.15 (0.12 to 0.19) 1.94 (1.82 to 2.07)
*Rate: incidence rates per 100 PY. Incidence rates for the registry data were standardised according to the age and sex distribution in the RA 
clinical trial programme overall analysis; for the RA clinical trial programme crude incidence is presented
†95% CI: approximate CIs based on the gamma distribution for registry data and exact Poisson CIs for the RA clinical trial programme.
 CORRONA, Consortium of Rheumatology Researchers of North America; IORRA, Institute of Rheumatology Rheumatoid Arthritis; NA, not 
available; NC, not calculated due to too few events (rates were only produced if at least five events were observed); NOAR, Norfolk Arthritis 
Register; PY, person-years; SRR, Swedish Rheumatology Quality of Care Register.
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Despite our efforts to address and minimise limitations 
inherent in using observational data to contextualise 
clinical trial data, some important limitations remain 
and must be considered when interpreting our results. 
These include: (1) registry-based cohorts may under-re-
port outcomes if patients leave the registry before events 
occur or are not adequately followed-up.35 36 (2) Data 
collection methods for events vary between the clinical 
studies and the registries. In the clinical programme, 
events are actively collected by physicians and often adju-
dicated; in the registries outcome capture differs and 
can be collected actively or through other systems (eg, 
linkages to external data sources). Despite these differ-
ences, the outcomes assessed here were defined and 
selected based on feasibility to assess with reasonable 
validity in both registries and clinical trial data, as well as 
being of clinical relevance. (3) Clinical trial programmes 
extensively use inclusion/exclusion criteria and there-
fore have more homogenous and selected populations 
compared with typical populations found in registries, 
which are typically more representative of the general 
patient population with RA. A clinical trial programme 
may also be enriched for aspects of the studied disease, 
for example, higher disease activity in RA.9 28 If these 
factors affect the outcome studied, bias may ensue. (4) 
All registries were established independently at different 
times without initial harmonisation of data definitions. 
Baseline and variable definitions were harmonised as 
much as feasible before analysing the data, but remaining 
variability across registries remains a potential limitation. 
(5) The influence of potential time-varying confounders, 
such as changes in treatment for RA, was not part of the 
predefined analysis plan, and the analyses were therefore 
limited to evaluating the influence of baseline covariates 
on infection rates. However, this approach is consistent 
with the typical methodology used in the analysis of clin-
ical trials, and as the ultimate goal of this work was to 
contextualise a clinical trial programme with registry 
data, evaluating baseline covariates as predictors of infec-
tion in these cohorts is appropriate. While the extent 
Figure 2 Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with 
RA from five RA registries and one RA clinical trial programme in the main analysis and two sensitivity analyses: (A) main 
analysis (main cohort); (B) main cohort, standardised for HAQ score in addition to sex and age and (C) restricted to biologicals-
naïve (MTX/DMARD-IR) patients, with 18 months truncated follow-up. Approximate CIs based on the gamma distribution for 
registry data and exact Poisson CIs for fostamatinib data. For panels (A) and (C), incidence rates for the registry data were 
standardised according to the age and sex distribution in the appropriate corresponding cohort (A: overall cohort, C: MTX-IR 
cohort) of the fostamatinib dataset; for fostamatinib, crude incidence is presented. For panel (B), incidence rates for the registry 
data were standardised according to the age, sex and HAQ score distribution in the overall cohort of the fostamatinib dataset; 
for fostamatinib, crude incidence is presented. CORRONA, Consortium of Rheumatology Research of North America; HAQ, 
Health Assessment Questionnaire; IORRA, Institute of Rheumatology Rheumatoid Arthritis; MTX/DMARD-IR, Methotrexate/
Disease Modifying Anti Rheumatic Drug-Incomplete Response; NOAR, Norfolk Arthritis Register; RA, rheumatoid arthritis; SRR, 
Swedish Rheumatology Quality of Care Register; 
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of either of these potential limitations cannot be fully 
known, the current study was designed to address them 
with a variety of sensitivity analyses, and the overall consis-
tency of results across the analyses lends additional weight 
to the overall findings. In addition, some of the sensitivity 
analyses provided insights consistent with prior literature 
of potential factors affecting variation in infection rates.
In conclusion, a coordinated analysis across multiple 
large RA registries provided stable background incidence 
rate estimates for infection events, and these estimates 
were valuable for the contextualisation of an RA clinical 
trial programme with limited placebo follow-up. This 
analysis demonstrates unique considerations needed 
when comparing infectious events between clinical trial 
and observational data and the need to consider creating 
more comparable cohorts and analyses for the most 
appropriate comparisons and contextualisation. Overall, 
our results provide a considerable improvement on reli-
ance on published studies alone, an attractive approach 
to contextualising safety data from clinical trials.
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